Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Obesity Rekated Cancer, Body Composition Changes, Survival, Mechanism. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA/CT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat/muscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.
Primary outcome measures
- Overall survival [Time frame: From date of diagnosis until the date of death from any cause, assessed up to 10 years]
Secondary outcome measures (2)
- Progression-free survival after diagnosis [Time frame: From date of diagnosis until the date of first documented progression , assessed up to 10 years]
- Time of recurrence and/or distant metastasis after diagnosis [Time frame: From date of diagnosis until the date of first documented recurrence and/or distant metastasis, whichever came first, assessed up to 10 years]
Eligibility criteria
Inclusion criteria
- Age ≥18 years, regardless of gender.
- Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted).
- No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy.
Exclusion criteria
- Patients with concurrent non-obesity-related malignancies.
- History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin).
- Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Peking union medical college hospital — Beijing
Identifiers
NCT: NCT07161167 · obesity-related cancer & BC